Last checked at 12 Oct 2018 10:29
Synairgen plc
('Synairgen' or the 'Company')
Result of General Meeting
Further to Synairgen's announcement of 25 September 2018, the Company is pleased to announce today the passing of the Resolutions at the General Meeting held earlier today. The Placing and Subscription remain conditional on Admission of the New Ordinary Shares to AIM, which is expected to take place at 8.00 a.m. on Monday 15 September 2018.
With effect from Admission, the Company will have 109,433,442 Ordinary Shares in issue, with no shares held in treasury. Shareholders may use this figure as the denominator by which they are required to notify their interest in, or change to their interest in, the Company under the Disclosure Guidance and Transparency Rules.
Following Admission, the shareholdings of the below Directors of the Company, who participated in the Fundraise, are as follows:
Director | Ordinary Shares held prior to the Fundraise | Ordinary Shares subscribed for in the Fundraise | Ordinary Shares held after the Fundraise | Percentage of the Enlarged Issued Share Capital held |
Richard Marsden
| 154,432
| 156,250
| 310,682 | 0.28% |
Dr Phillip Monk | 183,439 | 46,875 | 230,314 | 0.21% |
John Ward | 276,506 | 62,500 | 339,006 | 0.31% |
Capitalised terms in the text of this announcement have the meanings given to them in the Company's circular dated 26 September 2018.
For further enquiries, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Finance Director
Tel: + 44 (0) 23 8051 2800
finnCap
Geoff Nash, Max Bullen-Smith (Corporate Finance)
Alice Lane (ECM)
Tel: + 44 (0) 20 7220 0500
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott / Sukaina Virji / Laura Thornton
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5701
Notes for Editors
About Synairgen
Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Leveraging its scientific and clinical facilities at Southampton General Hospital, the Company uses in vitro and ex vivo models to progress opportunities into clinical development. The BioBank of human samples is used in these models to increase confidence in the likelihood of successful drug development.
Synairgen is currently running a two-part Phase II trial evaluating SNG001, the Company's wholly-owned inhaled interferon beta (IFN-beta) therapeutic candidate. The Phase II trial, called SG015, has been designed to assess the safety of SNG001 in COPD patients and its clinical benefit in these patients when they have a cold or flu infection, a major driver of COPD exacerbations.
Core to Synairgen's business strategy is the realisation of value via licensing transactions. In August 2015 the Company entered into a collaboration with Pharmaxis to develop an oral LOXL2 inhibitor to reduce fibrosis in patients with idiopathic pulmonary fibrosis (IPF). In December 2017 the collaboration agreement was amended as Pharmaxis took on full responsibility for the programme, with Synairgen receiving a £5 million upfront payment and circa 17% of any future net partnering proceeds from all fibrotic indications.
Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com
The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Richard Marsden | ||||
2. | Reason for the Notification | |||||
a) | Position/status | PDMR - CEO | ||||
b) | Initial notification/Amendment |
| ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Synairgen plc | ||||
b) | LEI | 213800IMMTOPPDF8HD24 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the Financial instrument, type of instrument |
| ||||
Identification code | GB00B0381Z20 | |||||
b) | Nature of the transaction | Purchase of Ordinary Shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: · Aggregated volume · Price |
N/A, single transaction as per 4c above | ||||
e) | Date of the transaction | 12 October 2018 | ||||
f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) | ||||
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Dr. Phillip Monk | ||||
2. | Reason for the Notification | |||||
a) | Position/status | PDMR - Chief Scientific Officer | ||||
b) | Initial notification/Amendment |
| ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Synairgen plc | ||||
b) | LEI | 213800IMMTOPPDF8HD24 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the Financial instrument, type of instrument |
| ||||
Identification code | GB00B0381Z20 | |||||
b) | Nature of the transaction | Purchase of Ordinary Shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: · Aggregated volume · Price |
N/A, single transaction as per 4c above | ||||
e) | Date of the transaction | 12 October 2018 | ||||
f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) | ||||
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | John Ward | ||||
2. | Reason for the Notification | |||||
a) | Position/status | PDMR - Finance Director | ||||
b) | Initial notification/Amendment |
| ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Synairgen plc | ||||
b) | LEI | 213800IMMTOPPDF8HD24 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the Financial instrument, type of instrument |
| ||||
Identification code | GB00B0381Z20 | |||||
b) | Nature of the transaction | Purchase of Ordinary Shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: · Aggregated volume · Price |
N/A, single transaction as per 4c above | ||||
e) | Date of the transaction | 12 October 2018 | ||||
f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) | ||||